Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) announced the successful completion of a pilot project with Kuano Ltd. that supports advancement of the company’s PNKP Inhibitor Technology (ONC010) through AI-enabled and quantum-based computational analysis. The project delivered molecular modeling and computational findings that strengthened Onco’s understanding of how its PNKP inhibitor and related analogs may interact with the target, producing a refined structural hypothesis for PNKP inhibition and establishing a framework for structure-based optimization and future evaluation.
The project also applied quantum-based computational methods to assess PNKP structural behavior and develop human PNKP structural models for follow-on analysis. According to the company, the results are expected to support future initiatives including quantum-based QSAR modeling, toxicity mapping and AI-assisted generative compound design, with the goal of improving compound prioritization and accelerating progress toward preclinical development.
This advancement could have significant implications for the field of oncology, as PNKP is a key enzyme involved in DNA repair pathways that cancer cells often exploit to resist treatment. By developing a potent inhibitor of PNKP, Onco-Innovations aims to sensitize tumors to radiation and chemotherapy, potentially improving outcomes for patients with solid tumors. The integration of AI and quantum computing into drug discovery represents a cutting-edge approach that may reduce development timelines and costs, while increasing the likelihood of identifying effective candidates.
For investors and the broader biotech industry, this pilot’s success demonstrates the practical application of advanced computational techniques in early-stage drug development. Onco-Innovations’ ability to leverage these tools could set a precedent for other companies exploring similar strategies. The company has secured an exclusive worldwide license to patented technology that targets solid tumours, and this pilot represents a step toward realizing the potential of that technology.
To view the full press release, visit https://ibn.fm/SdQqD. For the latest news and updates relating to ONNVF, see the company’s newsroom at https://ibn.fm/ONNVF.
